Cyrus Biotechnology
Cyrus Biotechnology develops computationally engineered biologics from natural proteins for therapeutic applications, with lead programs targeting severe autoimmune diseases and acute respiratory distress syndrome. The company uses protein design algorithms and laboratory methods to create novel variants and fusion proteins, aiming to provide superior efficacy and address unmet medical needs.
Facts
- HQ
- Seattle, Washington, US
- Sectors
- Biotechnology Research
- Founded
- 2014
- Type
- Corporation Seattle business license
- Employees
- 17
- Registered name
- Cyrus Biotechnology Inc Seattle business license
- Stage
- Series B
- Members see funding amounts. .
- Founders
- David Baker
Is this your organization? Claim it
Seattle’s UW research, Amazon alumni and military adjacency fuel startups building high-stakes, regulation-ready AI for biotech, finance and government
A Seattle high-school intern argues that strict school AI rules illuminated why AI must be disciplined in high-stakes domains, and describes how Seattle's research institutions (notably UW and the David Baker ecosystem), Amazon alumni, and military adjacency produce founders building accountable, regulation-ready AI for biotech, finance, and government.
Seattle’s Accipiter Bio Raises $12.7M, Partners with Pfizer and Kite Pharma to Advance AI-Designed Multi-Target Protein Therapies
Seattle biotech startup Accipiter Biosciences, founded by researchers from Nobel laureate David Baker's lab, secured $12.7 million and partnerships with Pfizer and Kite Pharma to develop AI-designed multi-target proteins aiming to improve disease treatment efficacy and reduce clinical trial costs.
Nobel Laureate David Baker Drives Protein Design Innovation and Startup Growth at University of Washington
David Baker, Nobel Prize winner and head of the Institute for Protein Design at the University of Washington, is focused on advancing protein design research and entrepreneurship, having helped spawn over 20 startups in Seattle's biotech hub. He plans to continue accelerating scientific innovation in the field, which develops new proteins for therapeutics, vaccines, and materials.
People
-
Lucas Nivon Executive Officer, Director, Co-Founder and Chief Executive Officer
-
Yifan Song Director, Co-founder and Chief Technology Officer
-
Erik Procko Executive, Chief Scientific Officer
Online
Questions about Cyrus Biotechnology
What is Cyrus Biotechnology?
Cyrus Biotechnology is a startup based in Seattle, Washington, US that develops computationally engineered biologics from natural proteins for therapeutic applications. Its lead programs target severe autoimmune diseases and acute respiratory distress syndrome.
What is Cyrus Biotechnology known for?
Cyrus Biotechnology uses protein design algorithms and laboratory methods to create novel protein variants and fusion proteins for therapeutic applications.
What has Cyrus Biotechnology been in the news for?
Ascend.vc reported in January 2026 on Seattle startups building regulation-ready AI for biotech, finance and government. GeekWire reported in December 2024 on David Baker’s protein design innovation and startup growth at University of Washington.
Who are the people behind Cyrus Biotechnology?
Lucas Nivon is co-founder, chief executive officer and executive officer at Cyrus Biotechnology. Yifan Song is co-founder and chief technology officer, and Erik Procko is chief scientific officer.
Who invested in Cyrus Biotechnology, and how much has it raised?
Members of Seattle Flow see Cyrus Biotechnology's funding rounds, amounts and investors on its Funding tab. Joining is free.
Where is Cyrus Biotechnology based?
Cyrus Biotechnology is based in Seattle, Washington, US.